Vanessa Ragaglia serves as the Senior Director of Toxicology & Project Champion at Larimar Therapeutics Inc., where she plays a pivotal role in advancing the safety and efficacy of innovative protein therapeutics aimed at treating orphan diseases. With a robust background in toxicology and a...
Vanessa Ragaglia serves as the Senior Director of Toxicology & Project Champion at Larimar Therapeutics Inc., where she plays a pivotal role in advancing the safety and efficacy of innovative protein therapeutics aimed at treating orphan diseases. With a robust background in toxicology and a keen understanding of the complexities of drug development, Vanessa oversees all nonclinical safety assessment work, reporting directly to the Chief Medical Officer. Her expertise encompasses the planning, design, and management of a wide array of toxicology studies, including repeat dose, genetic, reproductive, carcinogenicity, and juvenile safety assessments.
In her current role, Vanessa is instrumental in fostering collaboration across multiple departments, including discovery, clinical, regulatory, and project management teams. This cross-functional synergy is essential for ensuring that nonclinical safety data aligns with clinical objectives and regulatory requirements, ultimately facilitating the successful progression of therapeutic candidates through the development pipeline.
Key projects under Vanessa's leadership involve the strategic design and execution of comprehensive R&D plans that address the unique challenges associated with orphan drug development. Her adeptness in project management and competitive analysis enables her to navigate the rapidly evolving biotech landscape, ensuring that Larimar Therapeutics remains at the forefront of innovation. With a focus on assay development and cell culture techniques, Vanessa is committed to advancing the understanding of safety profiles for novel therapeutics, thereby contributing to the broader mission of improving patient outcomes in underserved populations. Her strategic vision and expertise are invaluable assets as Larimar Therapeutics continues to push the boundaries of what is possible in the realm of biotechnology.
